Category: Uncategorized

MedTech Cybersecurity & Supply Chain Disruption: Boston Scientific Discloses Cyber Incident Impacting Global Order Processing and Shipments – Wall Street Models Up to 700 bps Q3 Revenue Exposure

27/08/2026 Published by Pharma Biz

Key Development On August 26, 2026, global medical technology leader Boston Scientific Corp (NYSE: BSX) disclosed that a cybersecurity incident... Read more

Tags: #Global Trends

MedTech Cybersecurity & Supply Chain Disruption: Boston Scientific Discloses Cyber Incident Impacting Global Order Processing and Shipments – Wall Street Models Up to 700 bps Q3 Revenue Exposure

27/08/2026 Published by Pharma Biz

Key Development On August 26, 2026, South Korea’s SK Biopharmaceuticals (KRX: 326030) entered into a definitive worldwide licensing agreement valued... Read more

Category: Uncategorized

Tags: #M&A

Asia-Pacific Cardiometabolic Expansion: China NMPA Accepts Novo Nordisk’s Marketing Authorization Application for Oral Wegovy® (Semaglutide) to Contest Eli Lilly in $4.5 Billion Market

27/08/2026 Published by Pharma Biz

Key Development On August 27, 2026, Danish pharmaceutical leader Novo Nordisk (CPSE: NOVO-B / NYSE: NVO) announced that China’s National... Read more

Category: Uncategorized

Tags: #Global Trends

Neuroscience Licensing & Capital De-Risking: Biohaven Monetizes Lead Focal Epilepsy Candidate Opakalim (Kv7 Platform) to SK Biopharmaceuticals in $795 Million Strategic Divestment

27/08/2026 Published by Pharma Biz

Key Development On August 26, 2026, clinical-stage biopharmaceutical innovator Biohaven Ltd. (NYSE: BHVN) announced a definitive worldwide licensing agreement transferring... Read more

Category: Uncategorized

Tags: #Global Trends

Health Economics & Real-World Outcomes: Sustained Zepbound® (Tirzepatide) Use Associated with Up to 38% Reduction in Monthly Healthcare Costs Among Older Adults with Obesity After 12 Months

27/08/2026 Published by Pharma Biz

Key Development Eli Lilly and Company (NYSE: LLY) has published landmark Real-World Evidence (RWE) findings from a matched cohort study... Read more

Category: Uncategorized

Tags: #Global Trends

Precision Oncology Milestone: US FDA Approves Revolution Medicines’ Rasonque® (Daraxonrasib) as First-in-Class RAS(ON) Multiselective Inhibitor for Metastatic Pancreatic Cancer, Doubling Overall Survival to 13.2 Months

27/08/2026 Published by Pharma Biz

Key Development On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque® (daraxonrasib / RMC-6236), an oral... Read more

Category: Uncategorized

Tags: #Global Trends

Corporate Governance & Capital Expansion: Vidipha (HoSE: VDP) Insiders Completely Divest Equity and Subscription Rights as Incoming Major Shareholders Acquire >34% Stake to Fund EU-GMP Cephalosporin Facility

27/08/2026 Published by Pharma Biz

Key Development Central Pharmaceutical Joint Stock Company VIDIPHA (HoSE: VDP) has recorded a major restructuring of its shareholder register, coinciding... Read more

Category: Uncategorized

Tags: #Vietnam